MyoKardia reports positive data from phase 1b single-ascending dose trial of MYK-491
MyoKardia announced topline results from the Phase 1b single-ascending dose study of MYK-491. MYK-491 was generally well-tolerated and increases in cardiac contractility were observed. MYK-491 is MyoKardia’s most advanced activator molecule designed to increase contractility of the heart. December 11, 2018